Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof
US12312406B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2019 |
| Grant date | May 27, 2025 |
| Priority date | — |
| Expiry date | Sep 9, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An anti-B7-H3 antibody, a preparation method therefor, a conjugate and an application thereof. The anti-B7-H3 antibody comprises a complementarity determining region: one or more of heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3. A sequence of the complementarity determining region is as described in the specification. The anti-B7-H3 antibody is a fully human antibody, has a unique antigen binding epitope, and can specifically bind B7-H3 antigen on tumor cells. Moreover, the antibody can rapidly internalize into cells after binding to tumor cells, and can be used for ADC drug development to obtain better anti-tumor activity and efficacy to achieve the purpose of treating cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.